Novel Therapy Target in Metastatic Prostate Cancer
ConditionProstate Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorFudan University
About this trial
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed prostate cancer
metastatic disease confirmed by image examination
Patients who can undergo surgery or biopsy for prostate cancer
Able to provide informed consent
Disqualifiers
Patients diagnosed with other types of cancer besides prostate cancer
Not accessible to surgery sample
Patients fail to provide informed consent
Other situation that researchers think are unsuitable for this study
Trial population
Patients with metastatic prostate cancer especially metastatic castration resistant prostate cancer will be recruited for this study.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Tissue
Other interventionTissue will be derived from patients during a standard of care procedure
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: All patients1 intervention
Trial outcomes
Primary outcomes
1
Multiple omics features
Multi-omics information including genetic profiling results, transcriptional profiling results and epigenomic profiling results will be collected and analyzed.
Time frame
3 years2
Organoids successfully generated from metastatic prostate cancer
Successful isolation of prostate cancer organoids from surgical specimens of patients diagnosed with metastatic prostate cancer. We will calculate the culture efficiency and total number of organoids generated in our center.
Time frame
3 years3
Developing of biomarkers related to cancer metastasis and drug resistant
To search for biomarkers related to tumor metastasis and resistance by performing multi-omics analysis to surgery specimens derived from patients with metastatic prostate cancer.
Time frame
3 yearsSecondary outcomes
1
Animal models successfully generated from patient derived prostate cancer organoids
Prostate cancer organoids with clarified characteristics will be transplanted into mice to establish PDOX models.
Time frame
3 years2
Response of the prostate cancer organoids to the selected anti-cancer compounds
Organoid that are successfully cultured and characteristic clarified will be treated with the selected compounds to test their anti-cancer activity.
Time frame
3 years3
Response of the PDOX models to the selected anti-cancer compounds
PDOX models that successfully established will be treated with the selected compounds to test their anti-cancer activity.
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov